Company Filing History:

5 out of 277

The University of Alabama

patents

2 out of 647

The UAB Research Foundation (The University of Alabama at Birmingham)

patents

1 out of 1

Fuzians Biomedicals, Inc.

Univ. of Alabama at Birmingham

patents

6. 4 out of 832,891

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2015

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8933075 - Compounds useful as antiviral agents, compositions, and methods of use (2015-01-13),

2. 8466177 - Treating and preventing viral infections (2013-06-18),

3. 6844346 - Chromogenic substrates of sialidase and methods of making and using the same (2005-01-18),

4. 6812332 - Chromogenic substrates of sialidase and methods of making and using the same (2004-11-02),

5. 6512100 - Chromogenic substrates of sialidase and methods of making and using the same (2003-01-28),

6. 6509359 - Pyrrolidin-2-one compounds and their use as neuraminidase inhibitors (2003-01-21),

7. 6447991 - Smart aerogel (2002-09-10),

8. 6114386 - Inhibitors of bacterial sialidase (2000-09-05),

9. 6090609 - Crystallized N-terminal domain of influenza virus matrix protein M1 and (2000-07-18),

10. 5985859 - Methods of inhibiting bacterial sialidase (1999-11-16),

11. 5714509 - Inhibitors of bacterial sialidase and methods of making and using the (1998-02-03),

12. 5453533 - Inhibitors of influenza virus neuraminidase and methods of making and (1995-09-26),

Title: The Innovative Mind of Ming Luo: Pioneering Antiviral Therapies

Introduction

Ming Luo, a prominent inventor based in Birmingham, AL, has made significant contributions to the field of antiviral agents through his innovative research and patents. With a remarkable portfolio of 12 patents, he is at the forefront of developing compounds that hold the potential to transform the treatment and prevention of viral infections.

Latest Patents

Among his latest patents, Luo has described novel compounds known as 3-N-cycloalkyl-5-substituted-2-thioxothiazolidin-4-one derivatives, which have demonstrated efficacy in treating viral infections. These derivatives are not only significant for their therapeutic potential but also represent new pharmaceutical compositions designed for clinical application. Furthermore, he has also outlined compounds effective in the treatment and prevention of influenza and other viral infections, along with methods for utilizing these compositions in therapeutic settings.

Career Highlights

Ming Luo has garnered extensive experience in the research and development of antiviral therapies. His work, particularly at the University of Alabama, showcases his commitment to advancing medical science and enhancing public health through innovative pharmaceutical solutions.

Collaborations

Throughout his career, Ming Luo has collaborated with notable colleagues, including Stephen C. Johnson and Ashraf Saeed. These partnerships have enriched his research endeavors and contributed to the development of his groundbreaking inventions.

Conclusion

Ming Luo continues to exemplify the spirit of innovation in the realm of antiviral research. His dedication to improving human health through effective treatments makes him a valuable contributor to the scientific community and a noteworthy inventor in the field of pharmaceuticals. With each new patent, he is paving the way for future advancements that may one day revolutionize how we combat viral infections.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com